The treatment landscape for multiple myeloma has undergone significant advancements recently, largely due to the introduction of novel drug classes like bispecific antibodies and CAR T (chimeric antigen receptor T-cell) therapies. These innovative treatments are reshaping how the disease is managed, offering hope for patients with R/R multiple myeloma, a group that has traditionally faced...